ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jiang Long

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5122979556. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

A Spatially Directed Microneedle Patch Enables Intratumoral Co-Delivery of FOLFIRINOX, Surufatinib, and Anti-PD-1 for Chemo-Immunotherapy of Pancreatic Ductal … Last author DOI 10.1002/advs.76478 ↗
The scRNA-sequencing landscape of pancreatic ductal adenocarcinoma revealed distinct cell populations associated with tumor initiation and progression. Co-author DOI 10.1016/j.gendis.2024.101323 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ying Wang · 1 shared paper, 2025 · strength 0.27
- Paper The scRNA-sequencing landscape of pancreatic ductal adenocarcinoma revealed distinct cell populations associated with t… DOI 10.1016/j.gendis.2024.101323 ↗
Wentao Li · 1 shared paper, 2025 · strength 0.27
- Paper The scRNA-sequencing landscape of pancreatic ductal adenocarcinoma revealed distinct cell populations associated with t… DOI 10.1016/j.gendis.2024.101323 ↗
Tingting Kong · 1 shared paper, 2026 · strength 0.26
- Paper A Spatially Directed Microneedle Patch Enables Intratumoral Co-Delivery of FOLFIRINOX, Surufatinib, and Anti-PD-1 for C… DOI 10.1002/advs.76478 ↗
Yan Zheng · 1 shared paper, 2026 · strength 0.26
- Paper A Spatially Directed Microneedle Patch Enables Intratumoral Co-Delivery of FOLFIRINOX, Surufatinib, and Anti-PD-1 for C… DOI 10.1002/advs.76478 ↗
Zhengjun Qiu · 1 shared paper, 2026 · strength 0.26
- Paper A Spatially Directed Microneedle Patch Enables Intratumoral Co-Delivery of FOLFIRINOX, Surufatinib, and Anti-PD-1 for C… DOI 10.1002/advs.76478 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.